Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (232)	6/17/2004 3:32:55 AM
From: Thomas	Read Replies (1) \| Respond to of 671

Greetings to all, Courtesy of Google news alerts, see below for an announcement by MWG Biotech about getting into the siRNA re-agent business. This stock trades in Germany. At an EV @ ~1x revenues, this stock looks cheap. Tuck, what do you think? Weren't you looking for re-agent plays and finding the pickings slim? P.S. Any ideas what Dharmacon's revenues were? Cheers, Thomas <http://www.drugresearcher.com/news/news-NG.asp?id=52896> New player in RNAi reagents - 16/06/2004 - Germany’s MWG Biotech has launched its own line of small interfering RNA (siRNA) reagents, siMAX, encroaching into territory dominated by the likes of Qiagen, Dharmacon, Ambion, Proligo and Invitrogen. RNAi allows the inactivation of target genes by using complementary double stranded RNA which binds to messenger RNA and prevents protein transcription. It offers high specificity with a level of potency and stability which is far superior to that achievable with other technologies, such as antisense or ribozymes. As a result, RNAi has become the method of choice for a wide range of biomedical applications, in particular emerging as the best functional genomics screening method to identify and validate new drug targets. MWG’s decision to enter the market is an extension of the company’s existing product franchises in oligonucleotides and microarrays, polymerase chain reaction (PCR), sequencing and bioinformatics, all of which are used in functional genomics applications, according to Dr Wolfgang Pieken, the company’s chief scientific officer. "A perfect example for this is the combination of our MWG Inflammation Array, on which all known genes associated with the inflammatory process in humans are represented, with the matching set of siRNAs for complex functional genomics and proteomics analysis," he said. MWG has already built up a level of expertise in the manufacture of synthetic nucleic acids, so extending this to include siRNA was relatively simple, according to the company. It says it has refined its processes so that it can now make siRNA reagents with a coupling rate to their complementary nucleic acid sequences of 99 per cent, higher than the 70-80 per cent rate achieved with other products. The Company said it offers a portfolio of pre-designed siMAX libraries as well as a design service based on the MWG bioinformatics toolkit for customers who want to design their own siRNA. Analyst report: mwg-biotech.com Stock Symbol: mwg-biotech.com STOCK ISIN WKN SYMBOL MWG-BIOTECH AG DE0007300105 730010 NWU